Amoy Diagnostics Co FCF Margin

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.